Development of a Point of Care System for Automated Coma Prognosis

NCT ID: NCT03826407

Last Updated: 2023-02-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

33 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-10-01

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Electroencephalogram/event-related potentials (EEG/ERP) data will be collected from 50 participants in coma or other disorder of consciousness (DOC; i.e., Unresponsive Wakefulness Syndrome \[UWS\] or Minimally Conscious State \[MCS\]), clinically diagnosed using the Glasgow Coma Scale (GCS). For coma patients, EEG recordings will be conducted for up to 24 consecutive hours at a maximum of 5 timepoints, spanning 30 days from the date of recruitment, to track participants' clinical state. For DOC patients, there will be an initial EEG recording up to 24 hours, with possible subsequent weekly recordings up to 2 hours. An additional dataset from 40 healthy controls will be collected, each spanning up to a 12-hour recording period in order to formulate a baseline. Collected data are to form the basis for automatic analysis and detection of ERP components in DOC, using a machine learning paradigm. Salient features (i.e., biomarkers) extracted from the ERPs and resting-state EEG will be identified and combined in an optimal fashion to give an accurate indicator of prognosis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Problem: Coma is a state of unconsciousness with a variety of causes. Traditional tests for coma outcome prediction are mainly based on a set of clinical observations (e.g., pupillary constriction). Recently however, event-related potentials (ERPs; which are transient electroencephalogram \[EEG\] responses to auditory, visual, or tactile stimuli) have been introduced as useful predictors of a positive coma outcome (i.e., emergence). However, such tests require a skilled neurophysiologist, and such people are in short supply. Also, none of the current approaches has sufficient positive and negative predictive accuracies to provide definitive prognoses in the clinical setting.

Objective: The investigators will apply innovative machine learning methods to analyze patient EEGs (50 patients and 40 healthy controls) to develop a simple, objective, replicable, and inexpensive point of care system which can significantly improve the accuracy of coma prognosis relative to current methods. The physical requirements of the proposed system consist only of an EEG system (inexpensive in terms of medical equipment) and a conventional laptop computer.

Methodology: The investigators intend to extend the team's newest algorithms and develop machine learning tools for automatic analysis and detection of ERP components. Preliminary results by the team in this respect have been very promising. The most salient features (i.e., biomarkers) extracted from the ERP will be identified and combined in an optimal fashion to give an accurate indicator of prognosis. Features will be extracted from resting state brain networks and from network trajectories associated with the processing of ERP signals.

Significance: The proposed work will enable critical care physicians to assess coma prognosis with speed and accuracy. Thus, families and their health care team will be provided the most accurate information possible to guide discussions of goals of care and life-sustaining therapies in the context of dealing with the consequences of devastating neurological injury.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coma Disorder of Consciousness Minimally Conscious State Vegetative State Neuropathology

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DOC patients

Patients in coma (GCS score of 3-8) or with other disorder of consciousness, primarily Minimally Conscious State (MCS) or Unresponsive Wakefulness Syndrome (UWS; also known as vegetative state)

No interventions assigned to this group

Healthy Control

Matched healthy controls without current neurological diagnoses

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients (≥ 18 years of age) primarily admitted to the Intensive Care Units, Neurological Step Down Unit, or Coronary Care Unit at Hamilton General Hospital who are in coma with Glasgow Coma Scale (GCS) score of 3-8, or;
* Patients (≥ 18 years of age) who have other disorders of consciousness, primarily Minimally Conscious State (MCS) or Unresponsive Wakefulness Syndrome (UWS; also known as vegetative state).

Exclusion Criteria

* Severe liver failure (i.e., Child-Pugh Class C)
* Severe renal failure (i.e., Urea ≥ 40)
* Previous open-head injury
* Known primary and secondary central nervous system malignancy
* Known hearing impairment
* Previous intracranial pathology requiring neurosurgical interventions in the past 72 hours
* Anyone who is deemed medically unsuitable for this study by the attending intensivists

Healthy Controls:

Inclusion:

* ≥ 18 years of age
* no visual, language, learning, or hearing problems
* no history of neurological or psychiatric disorder
* not currently taking any medications that act on the central nervous system, such as antidepressants, anxiolytics, or anti-epileptics

Exclusion:

(During the COVID-19 pandemic only)

* ≥ 60 years of age
* have a weakened immune system
* have one or more of the COVID-19 high risk medical conditions, according to the government of Canada website: https://www.canada.ca/en/public-health/services/publications/diseases-conditions/people-high-risk-for-severe-illness-covid-19.html.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

Sponsor Role collaborator

Natural Sciences and Engineering Research Council, Canada

OTHER

Sponsor Role collaborator

Hamilton Health Sciences Corporation

OTHER

Sponsor Role collaborator

Brain Vision Solutions Inc.

UNKNOWN

Sponsor Role collaborator

McGill University

OTHER

Sponsor Role collaborator

McMaster University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

John F Connolly, PhD

Role: PRINCIPAL_INVESTIGATOR

McMaster University

Alison Fox-Robichaud, MD

Role: STUDY_CHAIR

Hamilton Health Sciences - Hamilton General site

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

McMaster University Hamilton Health Sciences / Hamilton General Hospital

Hamilton, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

References

Explore related publications, articles, or registry entries linked to this study.

Jones C. Glasgow coma scale. Am J Nurs. 1979 Sep;79(9):1551-3. No abstract available.

Reference Type BACKGROUND
PMID: 258560 (View on PubMed)

Chiappa KH, Hill RA. Evaluation and prognostication in coma. Electroencephalogr Clin Neurophysiol. 1998 Feb;106(2):149-55. doi: 10.1016/s0013-4694(97)00118-1.

Reference Type BACKGROUND
PMID: 9741776 (View on PubMed)

de Sousa LC, Colli BO, Piza MR, da Costa SS, Ferez M, Lavrador M. Auditory brainstem response: prognostic value in patients with a score of 3 on the Glasgow Coma Scale. Otol Neurotol. 2007 Apr;28(3):426-8. doi: 10.1097/MAO.0b013e3180326170.

Reference Type BACKGROUND
PMID: 17303965 (View on PubMed)

Logi F, Fischer C, Murri L, Mauguiere F. The prognostic value of evoked responses from primary somatosensory and auditory cortex in comatose patients. Clin Neurophysiol. 2003 Sep;114(9):1615-27. doi: 10.1016/s1388-2457(03)00086-5.

Reference Type BACKGROUND
PMID: 12948790 (View on PubMed)

Lew HL, Poole JH, Castaneda A, Salerno RM, Gray M. Prognostic value of evoked and event-related potentials in moderate to severe brain injury. J Head Trauma Rehabil. 2006 Jul-Aug;21(4):350-60. doi: 10.1097/00001199-200607000-00006.

Reference Type BACKGROUND
PMID: 16915010 (View on PubMed)

Kane NM, Butler SR, Simpson T. Coma outcome prediction using event-related potentials: P(3) and mismatch negativity. Audiol Neurootol. 2000 May-Aug;5(3-4):186-91. doi: 10.1159/000013879.

Reference Type BACKGROUND
PMID: 10859412 (View on PubMed)

Morlet D, Fischer C. MMN and novelty P3 in coma and other altered states of consciousness: a review. Brain Topogr. 2014 Jul;27(4):467-79. doi: 10.1007/s10548-013-0335-5. Epub 2013 Nov 27.

Reference Type BACKGROUND
PMID: 24281786 (View on PubMed)

Fischer C, Morlet D, Bouchet P, Luaute J, Jourdan C, Salord F. Mismatch negativity and late auditory evoked potentials in comatose patients. Clin Neurophysiol. 1999 Sep;110(9):1601-10. doi: 10.1016/s1388-2457(99)00131-5.

Reference Type BACKGROUND
PMID: 10479027 (View on PubMed)

Holeckova I, Fischer C, Giard MH, Delpuech C, Morlet D. Brain responses to a subject's own name uttered by a familiar voice. Brain Res. 2006 Apr 12;1082(1):142-52. doi: 10.1016/j.brainres.2006.01.089.

Reference Type BACKGROUND
PMID: 16703673 (View on PubMed)

Garrido MI, Kilner JM, Stephan KE, Friston KJ. The mismatch negativity: a review of underlying mechanisms. Clin Neurophysiol. 2009 Mar;120(3):453-63. doi: 10.1016/j.clinph.2008.11.029. Epub 2009 Jan 31.

Reference Type BACKGROUND
PMID: 19181570 (View on PubMed)

Sonnadara RR, Alain C, Trainor LJ. Occasional changes in sound location enhance middle latency evoked responses. Brain Res. 2006 Mar 3;1076(1):187-92. doi: 10.1016/j.brainres.2005.12.093. Epub 2006 Feb 17.

Reference Type BACKGROUND
PMID: 16487494 (View on PubMed)

Duncan CC, Barry RJ, Connolly JF, Fischer C, Michie PT, Naatanen R, Polich J, Reinvang I, Van Petten C. Event-related potentials in clinical research: guidelines for eliciting, recording, and quantifying mismatch negativity, P300, and N400. Clin Neurophysiol. 2009 Nov;120(11):1883-1908. doi: 10.1016/j.clinph.2009.07.045. Epub 2009 Sep 30.

Reference Type BACKGROUND
PMID: 19796989 (View on PubMed)

Schnakers C, Vanhaudenhuyse A, Giacino J, Ventura M, Boly M, Majerus S, Moonen G, Laureys S. Diagnostic accuracy of the vegetative and minimally conscious state: clinical consensus versus standardized neurobehavioral assessment. BMC Neurol. 2009 Jul 21;9:35. doi: 10.1186/1471-2377-9-35.

Reference Type BACKGROUND
PMID: 19622138 (View on PubMed)

Guldenmund P, Stender J, Heine L, Laureys S. Mindsight: diagnostics in disorders of consciousness. Crit Care Res Pract. 2012;2012:624724. doi: 10.1155/2012/624724. Epub 2012 Nov 14.

Reference Type BACKGROUND
PMID: 23213492 (View on PubMed)

Giacino JT, Fins JJ, Laureys S, Schiff ND. Disorders of consciousness after acquired brain injury: the state of the science. Nat Rev Neurol. 2014 Feb;10(2):99-114. doi: 10.1038/nrneurol.2013.279. Epub 2014 Jan 28.

Reference Type BACKGROUND
PMID: 24468878 (View on PubMed)

Laureys S, Celesia GG, Cohadon F, Lavrijsen J, Leon-Carrion J, Sannita WG, Sazbon L, Schmutzhard E, von Wild KR, Zeman A, Dolce G; European Task Force on Disorders of Consciousness. Unresponsive wakefulness syndrome: a new name for the vegetative state or apallic syndrome. BMC Med. 2010 Nov 1;8:68. doi: 10.1186/1741-7015-8-68.

Reference Type BACKGROUND
PMID: 21040571 (View on PubMed)

Armanfard N, Komeili M, Reilly JP, Mah R, Connolly JF. Automatic and continuous assessment of ERPs for mismatch negativity detection. Annu Int Conf IEEE Eng Med Biol Soc. 2016 Aug;2016:969-972. doi: 10.1109/EMBC.2016.7590863.

Reference Type BACKGROUND
PMID: 28268485 (View on PubMed)

Ghosh-Dastidar S, Adeli H, Dadmehr N. Principal component analysis-enhanced cosine radial basis function neural network for robust epilepsy and seizure detection. IEEE Trans Biomed Eng. 2008 Feb;55(2 Pt 1):512-8. doi: 10.1109/TBME.2007.905490.

Reference Type BACKGROUND
PMID: 18269986 (View on PubMed)

Guler I, Ubeyli ED. Multiclass support vector machines for EEG-signals classification. IEEE Trans Inf Technol Biomed. 2007 Mar;11(2):117-26. doi: 10.1109/titb.2006.879600.

Reference Type BACKGROUND
PMID: 17390982 (View on PubMed)

Cao C, Tutwiler RL, Slobounov S. Automatic classification of athletes with residual functional deficits following concussion by means of EEG signal using support vector machine. IEEE Trans Neural Syst Rehabil Eng. 2008 Aug;16(4):327-35. doi: 10.1109/TNSRE.2008.918422.

Reference Type BACKGROUND
PMID: 18701381 (View on PubMed)

Ravan M, Hasey G, Reilly JP, MacCrimmon D, Khodayari-Rostamabad A. A machine learning approach using auditory odd-ball responses to investigate the effect of Clozapine therapy. Clin Neurophysiol. 2015 Apr;126(4):721-30. doi: 10.1016/j.clinph.2014.07.017. Epub 2014 Aug 27.

Reference Type BACKGROUND
PMID: 25213349 (View on PubMed)

Khodayari-Rostamabad A, Reilly JP, Hasey GM, de Bruin H, Maccrimmon DJ. A machine learning approach using EEG data to predict response to SSRI treatment for major depressive disorder. Clin Neurophysiol. 2013 Oct;124(10):1975-85. doi: 10.1016/j.clinph.2013.04.010. Epub 2013 May 15.

Reference Type BACKGROUND
PMID: 23684127 (View on PubMed)

Wijdicks EF, Bamlet WR, Maramattom BV, Manno EM, McClelland RL. Validation of a new coma scale: The FOUR score. Ann Neurol. 2005 Oct;58(4):585-93. doi: 10.1002/ana.20611.

Reference Type BACKGROUND
PMID: 16178024 (View on PubMed)

Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet. 1975 Mar 1;1(7905):480-4. doi: 10.1016/s0140-6736(75)92830-5.

Reference Type BACKGROUND
PMID: 46957 (View on PubMed)

Armanfard N, Reilly JP, Komeili M. Local Feature Selection for Data Classification. IEEE Trans Pattern Anal Mach Intell. 2016 Jun;38(6):1217-27. doi: 10.1109/TPAMI.2015.2478471. Epub 2015 Sep 14.

Reference Type BACKGROUND
PMID: 26390448 (View on PubMed)

Armanfard N, Reilly JP, Komeili M. Logistic Localized Modeling of the Sample Space for Feature Selection and Classification. IEEE Trans Neural Netw Learn Syst. 2018 May;29(5):1396-1413. doi: 10.1109/TNNLS.2017.2676101. Epub 2017 Mar 21.

Reference Type BACKGROUND
PMID: 28333643 (View on PubMed)

Connolly JF, Reilly JP, Fox-Robichaud A, Britz P, Blain-Moraes S, Sonnadara R, Hamielec C, Herrera-Diaz A, Boshra R. Development of a point of care system for automated coma prognosis: a prospective cohort study protocol. BMJ Open. 2019 Jul 17;9(7):e029621. doi: 10.1136/bmjopen-2019-029621.

Reference Type DERIVED
PMID: 31320356 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CPG158287

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

CHRP 523461-18

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

ComaML2018

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.